Torrent Pharmaceuticals

Torrent Pharma specializes in cardiovascular, CNS, GI, and women’s healthcare products in India, with additional expertise in diabetology, pain management, and oncology.

Torrent Pharma faces a ₹3.12 crore GST penalty imposed by a Tamil Nadu tax officer. The order stems from discrepancies in tax filings or compliance issues under the Goods and Services Tax regime. Authorities in the state have issued the penalty following an audit or review of the company’s tax records.

Nov 2026scanx.tradeNews article

Geojit Financial Services publishes a research report recommending a **buy** rating for **Torrent Pharmaceuticals**, with a price target of **₹5,581**. The report highlights the company’s position in the pharmaceutical sector, though no specific financial or operational details are provided in the article.

Nov 2026TradingViewNews article

Torrent Pharma reports a **9.6% drop in Q2 net profit to Rs 534 crore** while revenue climbs **50.8% to Rs 4,979 crore**. The company’s EBITDA margin improves to **33.5%**, driven by the integration of JB Chemicals. Despite strong revenue growth, profit declines reflect operational adjustments post-acquisition.

Oct 2026The Times of IndiaNews article

Torrent Pharma reports a **10% drop in net profit to ₹534 crore** in Q2, despite a **51% revenue increase**. The company’s revenue for the first half of FY27 climbs **52.8% to ₹9,900 crore**, while net profit declines **3.4% to ₹1,100 crore**. The results highlight a revenue growth trend amid profit contraction.

Oct 2026The Hindu BusinessLineNews article